Medicare Enrolled
Dr. Rodolfo Batarse, M.D.
Internal Medicine · Rancho Mirage, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Batarse from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Batarse?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Batarse
Dr. Rodolfo Batarse is an internal medicine specialist in Rancho Mirage, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Batarse performed 10,044 Medicare services across 3,364 unique beneficiaries.
Between the years covered by Open Payments, Dr. Batarse received a total of $899,102 from 38 pharmaceutical and/or device companies across 1425 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Batarse is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 2% volume in CA
$899,102 industry payments
Medicare Practice Summary
Medicare Utilization ↗10,044
Medicare services
Top 2% in CA for internal medicine
3,364
Unique beneficiaries
$81
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~529 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
1,937 | $6 | $30 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
1,585 | $64 | $143 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
955 | $96 | $192 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
888 | $97 | $227 |
| Dialysis services for adults, 2-3 visits per month This code covers dialysis services for patients aged 20 or older who have 2 to 3 physician visits per month. |
809 | $238 | $500 |
| Remote patient monitoring device, 30 days Initial setup of devices for remote monitoring of body functions with daily data transmission or alerts. This service covers the first 30 days of the monitoring period. |
613 | $42 | $115 |
| Remote patient monitoring management, 20 min/month Management based on results from remote vital sign monitoring for the first 20 minutes per calendar month. |
611 | $40 | $100 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
514 | $18 | $47 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
514 | $137 | $342 |
| Monthly dialysis physician visit A monthly doctor's visit for patients aged 20 or older who are receiving dialysis treatment. |
259 | $164 | $400 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
240 | $11 | $50 |
| Remote physiologic monitoring setup and education Initial setup of remote monitoring equipment and patient education on its use. |
210 | $16 | $40 |
| Home dialysis services per month Monthly dialysis treatment provided in the patient's home for individuals aged 20 or older. |
163 | $236 | $465 |
| Dialysis services for patients 20 or older Dialysis treatment provided to patients aged 20 years or older, involving four or more physician visits per month. |
155 | $286 | $600 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
141 | $169 | $444 |
| Hemodialysis, single evaluation A dialysis procedure to filter waste from the blood, performed with a physician's evaluation. |
136 | $57 | $128 |
| New patient office visit, complex (60-74 min) | 125 | $168 | $384 |
| Remote vital sign monitoring management, each additional 20 minutes This code covers the time spent by a provider managing patient data from remote vital sign monitoring devices. It applies to each additional 20-minute increment beyond the initial monthly service period. |
59 | $32 | $85 |
| Nursing facility visit, moderate complexity A follow-up visit by a healthcare provider at a nursing facility for an established patient. The visit involves moderate medical decision making and takes at least 30 minutes. |
39 | $87 | $144 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
27 | $40 | $99 |
| Initial nursing facility care, high complexity An initial visit by a healthcare provider to a patient in a nursing facility involving a high level of medical decision making, lasting at least 45 minutes. |
23 | $148 | $258 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
22 | $62 | $156 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
19 | $105 | $222 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$899,102
Total received (2018-2024)
Avg $128,443/year across 7 years
Top 0% in CA for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
38
Companies
1,425
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$890,863 (99.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,434 (0.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$2,805 (0.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$79,977
2023
$84,541
2022
$132,687
2021
$116,546
2020
$89,099
2019
$256,438
2018
$139,813
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Bayer Healthcare Pharmaceuticals Inc.
$18,291
Fresenius USA Marketing, Inc.
$18,047
Otsuka America Pharmaceutical, Inc.
$13,790
Mallinckrodt Hospital Products Inc.
$11,130
Vifor Pharma, Inc.
$6,567
Ardelyx, Inc.
$5,696
AKEBIA THERAPEUTICS INC
$2,430
AstraZeneca Pharmaceuticals LP
$1,966
CALLIDITAS THERAPEUTICS US INC.
$1,153
Amgen Inc.
$481
Travere Therapeutics, Inc.
$145
Boehringer Ingelheim Pharmaceuticals, Inc.
$143
Otsuka Pharmaceutical Development & Commercialization, Inc.
$67
Aurinia Pharma U.S., Inc.
$46
Chiesi USA, Inc.
$27
Top 3 companies account for 62.7% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$182,638
Fresenius USA Marketing, Inc.
$167,508
Otsuka America Pharmaceutical, Inc.
$167,252
Bayer HealthCare Pharmaceuticals Inc.
$98,808
Relypsa, Inc.
$93,299
Vifor Pharma, Inc.
$55,661
Mallinckrodt Hospital Products Inc.
$35,729
Mallinckrodt Enterprises LLC
$31,891
Bayer Healthcare Pharmaceuticals Inc.
$28,582
AstraZeneca Pharmaceuticals LP
$18,130
Ardelyx, Inc.
$5,718
Janssen Pharmaceuticals, Inc
$3,570
AKEBIA THERAPEUTICS INC
$2,633
Horizon Therapeutics plc
$2,134
CALLIDITAS THERAPEUTICS US INC.
$1,228
AMAG Pharmaceuticals, Inc.
$751
Mallinckrodt LLC
$517
Aurinia Pharma U.S., Inc.
$427
Daiichi Sankyo Inc.
$376
Travere Therapeutics, Inc.
$319
Keryx Biopharmaceuticals, Inc.
$309
Calliditas Therapeutics US Inc.
$238
OPKO Pharmaceuticals, LLC
$221
Otsuka Pharmaceutical Development & Commercialization, Inc.
$182
ARBOR PHARMACEUTICALS, INC.
$154
Boehringer Ingelheim Pharmaceuticals, Inc.
$143
BAXTER HEALTHCARE
$138
AbbVie, Inc.
$125
La Jolla Pharmaceutical Company
$123
Novartis Pharmaceuticals Corporation
$96
GlaxoSmithKline, LLC.
$32
PFIZER INC.
$31
ANI Pharmaceuticals, Inc.
$30
Chiesi USA, Inc.
$27
Lilly USA, LLC
$22
Shire North American Group Inc
$22
Ultragenyx Pharmaceutical Inc.
$20
Alexion Pharmaceuticals, Inc.
$19
Top 3 companies account for 57.5% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMITIZA · AURYXIA · Aranesp · Auryxia · BASAGLAR · BENLYSTA · CHANTIX · CRYSVITA · Dialyzers · ELFABRIO · ELIQUIS · ENTRESTO · EPOGEN · Edarbi · FARXIGA · FERAHEME · FLOSEAL · GIAPREZA · IBSRELA · IMLYGIC · INJECTAFER · INVOKANA · JARDIANCE · JYNARQUE · KORSUVA · KRYSTEXXA · Kerendia · Korsuva · LOKELMA · LUPKYNIS · Mavyret · Not Product Related · PURIFIED CORTROPHIN GEL · Parsabiv · RAYALDEE · Rayaldee · Rayaldee (old) · Renal - PD · SAMSCA · SOLIRIS · TAGRISSO · TARPEYO · TAVNEOS · TERLIVAZ · Vafseo · Velphoro · Veltassa · XPHOZAH 30 MG
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (99%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in internal medicine and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for internal medicine in CA.
Geographic Context
Internal medicine physicians within 10 mi
211
Per 100K population
8.6
County median income
$89,672
Nearest hospital
EISENHOWER MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Batarse is a clinical cardiology specialist, with above-average Medicare volume (top 2% in CA), with speaking/promotional industry engagement in the top 0% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Batarse experienced with epoetin alfa injection (procrit) for anemia?
Based on Medicare claims data, Dr. Batarse performed 1,937 epoetin alfa injection (procrit) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Batarse receive payments from pharmaceutical companies?
Yes. Dr. Batarse received a total of $899,102 from 38 companies across 1,425 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Batarse's costs compare to other internal medicine physicians in Rancho Mirage?
Dr. Batarse's average Medicare payment per service is $81. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Batarse) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Rancho Mirage
Browse internal medicine physicians in Rancho Mirage ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in CA
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in CA
Which CA internal medicine physicians receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Fresenius USA Marketing, Inc. Payments to Doctors
See all physicians who received payments from Fresenius USA Marketing, Inc.
By company
Otsuka America Pharmaceutical, Inc. Payments to Doctors
See all physicians who received payments from Otsuka America Pharmaceutical, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology